Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arlocabtagene Autoleucel (BMS-986393) Combinations in Relapsed/Refractory Multiple Myeloma
NCT06121843Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2024
- Primary completion
- Aug 2028
- Countries
- 2
01
Overview
Phase 1, open-label trial of arlocabtagene autoleucel in multiple myeloma (MM) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events at 2 years, Incidence of serious adverse events at 2 years and 4 more. Started Feb 2024; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06121843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121843.